Sharemaestro company-news research for Neumora Therapeutics, Inc. (NMRA), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Insufficient evidence
Company news sentiment
Latest NMRA news and sentiment
Neumora Therapeutics, Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The dash means no score; it is not a neutral observation.
Observed headline tone50/100
→
Published 30-day score50/100
Latest source headline
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Moderate Buy" by Analysts
MarketBeat · 19 Sep 2026 10:18
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
Available information
2 current stories are mapped specifically to NMRA.
Why there is no score
The stories agree, but freshness-weighted evidence is only 0.000.
Confidence is 0/100, below the threshold for a firm score.
—/100
News scoreNo qualifying directional evidence
0/100
Confidencethin evidence
0%/100
Company news2 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
17 Sep02 Oct16 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness1
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks23 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 0.4757-4.8%
02 Oct 202650USD 0.4999-26.2%
25 Sep 202650USD 0.6776-7.2%
18 Sep 202650USD 0.73-29.8%
11 Sep 202650USD 1.04-20.6%
04 Sep 202651USD 1.31-5.8%
28 Aug 202650USD 1.39-14.7%
21 Aug 202650USD 1.63+1.9%
Insufficient evidence
News subjects
What is shaping the score
Analyst action551 stories · 50%
Market update501 stories · 50%
Source mix
Where the evidence comes from
MarketBeat551 stories · 50%
Schaeffer's Investment Research501 stories · 50%
Recurring subjects
Subjects appearing most often
Unusual Volume1Split1Options1Life Sciences1Financial Markets1Earnings1Biotech1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
05 May50 neutral11 Oct 22:31
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 11 Oct 22:31 | 50 | +0 | 0/100 (-15) | 2 (-13) | Insufficient |
| 19 Sep 23:59 | 50 | +0 | 15/100 (0) | 15 (-2) | Provisional |
| 18 Sep 23:59 | 50 | -1 | 15/100 (-11) | 17 (-16) | Provisional |
| 04 Sep 23:59 | 51 | +1 | 26/100 (+7) | 33 (-1) | Provisional |
| 31 Aug 23:59 | 50 | +0 | 19/100 (-2) | 34 (-2) | Provisional |
| 29 Aug 23:59 | 50 | +0 | 21/100 (-7) | 36 (-11) | Provisional |
| 25 Aug 23:59 | 50 | +0 | 28/100 (+1) | 47 (+1) | Provisional |
| 24 Aug 23:59 | 50 | +1 | 27/100 (-6) | 46 (-2) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 2 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
No directional evidence to attribute yet
Company news can still be read below. Influence bars appear when a current story qualifies for the directional score.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Analyst actionNot used in direction
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have issued a "Moderate Buy" rating for Neumora Therapeutics (NASDAQ:NMRA), with an average 12-month price target of $6.57, despite several recent target reductions. The company's shares opened at $0.73, near their 52-week low, and have seen continued insider selling totaling ove…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Analysts have issued a "Moderate Buy" rating for Neumora Therapeutics (NASDAQ:NMRA), with an average 12-month price target of $6.57, despite several recent target reductions. The company's shares opened at $0.73, near their 52-week low, and have seen continued insider selling totaling over $700,000 in the last 90 days. Neumora Therapeutics, a clinical-stage biopharmaceutical company, recently beat earnings estimates with a quarterly loss of $0.23 per share.
- Published
- 19 Sep 2026 10:18
- News subject
- Analyst action
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Biotech Options Buzz: UTHR, NMRA, EWTX
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits. United Therapeutics options …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits. United Therapeutics options volume is running at 31.7 times the usual intraday amount, with 70,000 contracts exchanged so far. Calls and puts are evenly split at 35,000 contracts apiece. UTHR is down 0.2% at $496.38, after CEO Martine Rothblatt's family trust exercised 9,500 options and sold the matching shares under a Rule 10b5-1 plan l
- Published
- 18 Sep 2026 15:46
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 27.6d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
BiotechOptionsSplitUnusual Volume
Earlier company news
NMRA news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 91 older NMRA headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to NMRA, but the headline and available text are not mainly about Neumora Therapeutics, Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of NMRA sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.